#None #San Francisco #glaucoma #Perfuse Therapeutics #PER-001

Positive Results from Phase 2 Clinical Trials

Perfuse Therapeutics, a visionary biopharmaceutical company focused on ischemia-driven ocular diseases, recently reported promising outcomes from their Phase 2 clinical trials involving their innovative treatment, PER-001. This ground-breaking therapy is designed to combat the primary causes of blindness: glaucoma and diabetic retinopathy.

Overview of the Trials

The double trials, each spanning six months, were randomized and controlled, aimed at evaluating the efficacy of PER-001, which functions as an endothelin antagonist. This first-of-its-kind treatment, delivered through a dissolvable implant, is injected intravitreal every six months. Results indicated a statistically significant improvement in vision for patients compared with control groups in both trials.

Addressing the Underlying Causes of Blindness

Perfuse Therapeutics’ approach is to focus not merely on symptomatic relief, but to directly address the underlying pathologies resulting in vision loss. PER-001 aims to enhance retinal blood flow, thereby preventing the significant cell death commonly seen in glaucoma and diabetic retinopathy. The initial findings are a beacon of hope, suggesting that PER-001 could potentially alter the progression of these ocular diseases, reversing vision impairment rather than simply halting its advance.

Plans are already in place to initiate Phase 2b/3 trials, expected to begin in the later half of 2025.

Glaucoma: The Silent Thief of Sight

Currently, glaucoma is acknowledged as a leading cause of irreversible blindness affecting millions globally. Many patients remain unaware of their condition. Traditional treatments often focus on lowering intraocular pressure (IOP), but research indicates that reducing IOP alone does not guarantee sustained visual function. In a recent Phase 2a trial, 22.2% of low-dose and 37.5% of high-dose patients reported a noticeable improvement of seven decibel (dB) or more in a specified retinal area, showcasing an 8 to 14 times better response than established treatments.

Remarkably, no patients receiving PER-001 experienced a loss of vision, contrasting sharply with a 12.5% loss rate in the control group. Data released during the Association for Research in Vision and Ophthalmology (ARVO) meeting in May reinforces the promise of PER-001 with significant improvements in metrics measuring blood flow and optic nerve function.

Dr. Joel Schuman, a prominent figure in ophthalmic research, emphasized the revolutionary nature of this trial, stating that for the first time, neuroenhancement in existing optic nerve fibers was observed, pointing to a paradigm shift in glaucoma management.

Progressing Treatment for Diabetic Retinopathy

Diabetic retinopathy continues to be a major threat to vision for millions living with diabetes. Statistics reveal that it is the primary cause of blindness among working-age adults globally. Traditional treatments have primarily aimed to stabilize structural outcomes, rather than offering substantial improvement in visual acuity. In the Phase 2a diabetic retinopathy trial, PER-001 demonstrated crucial enhancements in visual function metrics, with high-dose participants experiencing an average improvement of 0.9 dB in contrast sensitivity, and 5.5 and 5.1 letter gains in visual acuity over six months, compared to declines seen in control participants.

These results affirm the effectiveness of targeting the endothelin pathway, with structural improvements in macular ischemia, microaneurysms, and leakage being observed across all treatment groups.

Dr. Arshad Khanani, an expert in ophthalmology, elaborated on the significance of these findings. He indicated that this marks the first time an experimental therapy improved visual function in diabetic retinopathy patients in clinical studies.

Conclusion

In sum, the results from these Phase 2 trials showcase the potential for PER-001 to offer a transformative approach to treating glaucoma and diabetic retinopathy. With patient safety and tolerability confirmed in early studies, Perfuse Therapeutics is set to forge ahead with larger pivotal trials, aiming to bring this promising treatment to market within the coming years. As the path forward unfolds, anticipation grows around what PER-001 could mean for those suffering from these sight-threatening conditions.

For additional information, please visit Perfuse Therapeutics for more insights into their pioneering research and developments.